WORLDWIDE MARKET FOR PROPHYLACTIC AND
THERAPEUTIC VACCINES TO APPROACH $10 BILLION BY 2006
New developments in vaccine
technology that have emerged over the past decade have transformed this
relatively lackluster, price-competitive market sector into a
technology-driven industry characterized by increasing annual growth rates
that approached 10% during the late 1990s. During this period, market
growth was spurred by introduction of recombinant vaccines, both of which
will continue to contribute substantially to market growth throughout the
forecast period.
According to a
soon-to-be-released updated study from Business Communications Company,
Inc. (www.bccresearch.com)
RC-171R The Worldwide Market for Prophylactic and Therapeutic
Vaccines, the worldwide market for prophylactic and therapeutic
vaccines is estimated to be $5.8 billion in 2001. Growing at an AAGR
(average annual growth rate) of 11.6%, this market is expected to approach
$10 billion in 2006.
Prophylactic vaccines for
children and adults have been the mainstays of this market and although
dramatic innovations in these preventive products are not anticipated,
this category will enjoy continued modest growth. Pediatric prophylactic
vaccines make up 58% of the current market, but will show the slowest
growth, at an AAGR of 8.7% through 2006. Adult prophylactic vaccines are
the second largest group with sales of nearly $2.4 billion in 2001 and are
expected to rise at an AAGR of 10.1% to over $3.8 billion in 2006.
A tidal wave of growth in the
vaccines market is expected with the introduction of therapeutic vaccines
currently in development to treat acquired-immune deficiency syndrome
(AIDS), cancer and other major diseases. Deoxyribonucleic acid (DNA)- and
protein-based therapeutic vaccines show tremendous promise in treating
viral infections, and vaccines that boost the immune response to cancerous
cells will add a powerful new component to standard treatments for cancer.
Therapeutic vaccines will feature growth of over 100% on average per year
through the period, but by 2006 will still make up only 10.5% of the
market.
Worldwide Market for Prophylactic and
Therapeutic Vaccines, through 2006
($ Millions)
| |
2001
|
2006
|
AAGR% 2001-2006
|
|
Pediatric prophylactic
vaccines
|
3,360
|
5,090
|
8.7
|
|
Adult prophylactic
vaccines
|
2,370
|
3,840
|
10.1
|
|
Therapeutic vaccines
|
30
|
1,050
|
103.6
|
|
Total
|
5,760
|
9,980
|
11.6
|
Worldwide Market for Prophylactic
and Therapeutic Vaccines, 2001- 2006
($ Millions)
RC-171R The Worldwide Market for Prophylactic
and Therapeutic Vaccines - Updated Edition
Published: October 2001
Data and analysis provided courtesy of
BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant Street, Norwalk, CT
06855, Telephone: (203) 853-4266; ext. 309, Email: publisher@bccresearch.com |
